Additionally, the combination therapy may concurrently target both amyloidogenic (via BACE1 inhibition) and tau-related (via GSK-3β/CDK5 modulation) mechanisms, offering broader efficacy against hallmark features of AD pathology. Here, CDK5 is linked to Alzheimer disease.